These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31521062)

  • 1. Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study.
    Lisinski A; Hieronymus F; Näslund J; Nilsson S; Eriksson E
    Neuropsychopharmacology; 2020 Feb; 45(3):553-560. PubMed ID: 31521062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
    Hieronymus F; Lisinski A; Nilsson S; Eriksson E
    Lancet Psychiatry; 2019 Sep; 6(9):745-752. PubMed ID: 31303567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo.
    Lisinski A; Hieronymus F; Nilsson S; Eriksson E
    Transl Psychiatry; 2022 Apr; 12(1):160. PubMed ID: 35422023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors.
    Sheehan DV; Mancini M; Wang J; Berggren L; Cao H; Dueñas HJ; Yue L
    Hum Psychopharmacol; 2016 Jan; 31(1):53-63. PubMed ID: 26331440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis.
    Hieronymus F; Lisinski A; Eriksson E; Østergaard SD
    Transl Psychiatry; 2021 Apr; 11(1):249. PubMed ID: 33907188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
    Carter NJ; McCormack PL
    CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duloxetine versus other anti-depressive agents for depression.
    Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006533. PubMed ID: 23076926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression.
    Hieronymus F; Emilsson JF; Nilsson S; Eriksson E
    Mol Psychiatry; 2016 Apr; 21(4):523-30. PubMed ID: 25917369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials.
    Harada E; Kato M; Fujikoshi S; Wohlreich MM; Berggren L; Tokuoka H
    Int J Clin Pract; 2015 Oct; 69(10):1139-48. PubMed ID: 25980552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?
    Fava M; Mallinckrodt CH; Detke MJ; Watkin JG; Wohlreich MM
    J Clin Psychiatry; 2004 Apr; 65(4):521-30. PubMed ID: 15119915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
    Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
    Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
    J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
    Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
    J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of pretreatment with antidepressants on the efficacy of duloxetine in terms of mood symptoms and functioning: an analysis of 15 pooled major depressive disorder studies.
    Barros BR; Schacht A; Happich M; Televantou F; Berggren L; Walker DJ; Dueñas HJ
    Prim Care Companion CNS Disord; 2014; 16(5):. PubMed ID: 25667808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine in treatment of anxiety symptoms associated with depression.
    Dunner DL; Goldstein DJ; Mallinckrodt C; Lu Y; Detke MJ
    Depress Anxiety; 2003; 18(2):53-61. PubMed ID: 12964171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials.
    Hengartner MP; Jakobsen JC; Sørensen A; Plöderl M
    PLoS One; 2020; 15(2):e0229381. PubMed ID: 32101579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
    Shelton RC; Andorn AC; Mallinckrodt CH; Wohlreich MM; Raskin J; Watkin JG; Detke MJ
    Int Clin Psychopharmacol; 2007 Nov; 22(6):348-55. PubMed ID: 17917553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.